
CNBC’s Jim Cramer and the ‘Squawk on the Street’ team break down shares of Biohaven Pharmaceuticals after drug giant Pfizer agreed to acquire the company for $11.6 billion.
CNBC’s Jim Cramer and the ‘Squawk on the Street’ team break down shares of Biohaven Pharmaceuticals after drug giant Pfizer agreed to acquire the company for $11.6 billion.